RB1 mutations and second primary malignancies after hereditary retinoblastoma

Fam Cancer. 2012 Jun;11(2):225-33. doi: 10.1007/s10689-011-9505-3.

Abstract

Survivors of hereditary retinoblastoma have a high risk of second primary malignancies, but it has not been investigated whether specific RB1 germline mutations are associated with greater risk of second primary malignancies in a large cohort. We conducted a retrospective cohort study of 199 survivors of hereditary retinoblastoma with a documented RB1 germline mutation diagnosed between 1905 and 2005. In total, 44 hereditary retinoblastoma survivors developed a second primary malignancy after a median follow-up of 30.2 years (range 1.33-76.0). A significantly increased risk of second primary malignancy was observed among carriers of one of the 11 recurrent CGA>TGA nonsense RB1 mutations (hazard ratio (HR) = 3.53; [95% confidence interval (CI) = 1.82-6.84]; P = .000), and there was a significantly lower risk for subjects with a low penetrance mutation (HR = .19; [95% CI = .05-.81]; P = .025). Our findings suggest a genotype-phenotype correlation for second primary cancers of retinoblastoma survivors and may impact on long-term surveillance protocols of patients with hereditary retinoblastoma, if confirmed by future studies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Codon, Nonsense
  • Cohort Studies
  • Follow-Up Studies
  • Genetic Association Studies
  • Germ-Line Mutation
  • Humans
  • Infant
  • Middle Aged
  • Models, Genetic
  • Mutation*
  • Neoplasms, Second Primary / genetics*
  • Neoplasms, Second Primary / mortality
  • Netherlands
  • Proportional Hazards Models
  • Retinal Neoplasms / genetics*
  • Retinal Neoplasms / mortality
  • Retinoblastoma / genetics*
  • Retinoblastoma / mortality
  • Retinoblastoma Protein / genetics*
  • Retrospective Studies
  • Survivors
  • Young Adult

Substances

  • Codon, Nonsense
  • Retinoblastoma Protein